Arcutis Biotherapeutics
ARQT
ARQT
106 hedge funds and large institutions have $895M invested in Arcutis Biotherapeutics in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 31 increasing their positions, 29 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
7% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 29
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3% less capital invested
Capital invested by funds: $925M → $895M (-$29.1M)
Holders
106
Holding in Top 10
3
Calls
$2.88M
Puts
$445K
Top Buyers
| 1 | +$24.1M | |
| 2 | +$17.2M | |
| 3 | +$4.98M | |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$4.12M |
| 5 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$4.09M |
Top Sellers
| 1 | -$175M | |
| 2 | -$18.2M | |
| 3 | -$7.21M | |
| 4 |
Norges Bank
Oslo,
Norway
|
-$3.93M |
| 5 |
Citigroup
New York
|
-$2.09M |